ESG Highlights & Holdings — AbbVie

April 13, 2020 — Since its separation from Abbott Laboratories in 2013, AbbVie has flourished into a global company with a team of over 30,000 scientists, researchers, manufacturers, and regulatory experts, and it treats upwards of 30 million patients in 175 countries each year. In recent weeks, AbbVie has proven its dedication to patients across the globe by joining the effort in combating the spread of COVID-19. AbbVie has given up patent rights for one of its HIV drugs, Kaletra, in order to ensure its supply as global authorities repurpose existing drugs to treat the virus. AbbVie is the first among its peers to take this drastic step, setting an example for other drugmakers as the COVID-19 pandemic advances.